Literature DB >> 21619550

Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage.

Fan Lian1, Xiangbin Xing, Gang Yuan, Claus Schäfer, Sandra Rauser, Axel Walch, Christoph Röcken, Martin Ebeling, Matthew B Wright, Roland M Schmid, Matthias P A Ebert, Elke Burgermeister.   

Abstract

Bile acids from duodenogastric reflux promote inflammation and increase the risk for gastro-oesophageal cancers. FXR (farnesoid X receptor/NR1H4) is a transcription factor regulated by bile acids such as CDCA (chenodeoxycholic acid). FXR protects the liver and the intestinal tract against bile acid overload; however, a functional role for FXR in the stomach has not been described. We detected FXR expression in the normal human stomach and in GC (gastric cancer). FXR mRNA and protein were also present in the human GC cell lines MKN45 and SNU5, but not in the AGS cell line. Transfection of FXR into AGS cells protected against TNFα (tumour necrosis factor α)-induced cell damage. We identified K13 (keratin 13), an anti-apoptotic protein of desmosomes, as a novel CDCA-regulated FXR-target gene. FXR bound to a conserved regulatory element in the proximal human K13 promoter. Gastric expression of K13 mRNA was increased in an FXR-dependent manner by a chow diet enriched with 1% (w/w) CDCA and by indomethacin (35 mg/kg of body weight intraperitoneal) in C57BL/6 mice. FXR-deficient mice were more susceptible to indomethacin-induced gastric ulceration than their WT (wild-type) littermates. These results suggest that FXR increases the resistance of human and murine gastric epithelial cells to inflammation-mediated damage and may thus participate in the development of GC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619550     DOI: 10.1042/BJ20102096

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

Review 2.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

3.  Bile acids down-regulate caveolin-1 in esophageal epithelial cells through sterol responsive element-binding protein.

Authors:  Elke Prade; Moritz Tobiasch; Ivana Hitkova; Isabell Schäffer; Fan Lian; Xiangbin Xing; Marc Tänzer; Sandra Rauser; Axel Walch; Marcus Feith; Stefan Post; Christoph Röcken; Roland M Schmid; Matthias P A Ebert; Elke Burgermeister
Journal:  Mol Endocrinol       Date:  2012-04-03

4.  Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors.

Authors:  Nidhi Singh; Manisha Yadav; Abhishek Kumar Singh; Harish Kumar; Shailendra Kumar Dhar Dwivedi; Jay Sharan Mishra; Anagha Gurjar; Amit Manhas; Sharat Chandra; Prem Narayan Yadav; Kumaravelu Jagavelu; Mohammad Imran Siddiqi; Arun Kumar Trivedi; Naibedya Chattopadhyay; Sabyasachi Sanyal
Journal:  Mol Endocrinol       Date:  2014-03-05

Review 5.  The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.

Authors:  Maja Stojancevic; Karmen Stankov; Momir Mikov
Journal:  Can J Gastroenterol       Date:  2012-09       Impact factor: 3.522

6.  Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death.

Authors:  U Beyer; S K Krönung; A Leha; L Walter; M Dobbelstein
Journal:  Cell Death Differ       Date:  2015-05-29       Impact factor: 15.828

7.  MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR.

Authors:  Jian-Hua Duan; Long Fang
Journal:  Tumour Biol       Date:  2014-08-06

Review 8.  Novel insight into mechanisms of cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

Review 9.  Bile acid signaling in metabolic disease and drug therapy.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

Review 10.  Sex differences feed into nuclear receptor signaling along the digestive tract.

Authors:  Angela E Dean; François Reichardt; Sayeepriyadarshini Anakk
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-07-14       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.